Having trouble accessing articles? Reset your cache.

Lixisenatide: Phase III data

Top-line data from the double-blind, Asian Phase III GETGOAL-L-ASIA trial in 311 patients inadequately controlled with basal insulin showed

Read the full 195 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE